Cargando…
First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and -Preliminary Dynamics of Neuroprotectant 2-Iminobiotin in Healthy Subjects
BACKGROUND: 2-iminobiotin (2-IB) is an investigational neuroprotective agent in development for the reduction of brain cell injury after cerebral hypoxia-ischemia. OBJECTIVE: The present first-in-human study evaluated the safety, tolerability, pharmacokinetics (PK) and -dynamics (PD) of 2-IB in heal...
Autores principales: | van Hoogdalem, Ewoud-Jan, Peeters-Scholte, Cacha M.P.C.D., Leufkens, Paul W.T.J., Hartstra, Jan, van Lier, Jan J., de Leede, Leo G.J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579265/ https://www.ncbi.nlm.nih.gov/pubmed/31625480 http://dx.doi.org/10.2174/1574884714666191017111109 |
Ejemplares similares
-
Neuroprotection after cardiac arrest with 2-iminobiotin: a single center phase IIa study on safety, tolerability, and pharmacokinetics
por: Admiraal, M. M., et al.
Publicado: (2023) -
2-iminobiotin, a selective inhibitor of nitric oxide synthase, improves memory and learning in a rat model after four vessel occlusion, mimicking cardiac arrest
por: Peeters-Scholte, Cacha, et al.
Publicado: (2023) -
2-Iminobiotin Superimposed on Hypothermia Protects Human Neuronal Cells from Hypoxia-Induced Cell Damage: An in Vitro Study
por: Zitta, Karina, et al.
Publicado: (2018) -
Rethinking, reducing, and refining the classical oral tyramine challenge test of monoamine oxidase (MAO) inhibitors
por: van Hoogdalem, Ewoud‐Jan, et al.
Publicado: (2023) -
Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers
por: Hodges, Michael R., et al.
Publicado: (2023)